VEGFA and neoplasm: To investigate whether background of the BALB/c substrain affects the metastatic ability of the CT26 tumor after cisplatin treatment, the expression levels of MMP2 and VEGF proteins were examined in CT26 syngeneic tumors obtained from the three BALB/c substrains after cisplatin treatment for 14 days.